Loading market dashboard
Binah Capital Group, Inc.
BCGFinancial ServicesNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C inhibi
AstraZeneca's IMFINZIÂ (durvalumab) in combination with Bacillus Calmette-GuÃrin (BCG) induction and maintenance therapy has been approved in the US for the
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). The approval by the Food and Drug Administration (FDA) is based on positive results from the POTOMAC Phase III trial which were presented at the European Society for Medical Oncology (ESMO) Congress 2025 and s.
TVS Motor Company, part of TVS VENU, has been ranked #1 globally in the âDurable Consumer Goods' category in the annual âBest Stocks in the World', ranking
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration has accepte
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a vertically integrated commercial-stage immunotherapy company, today announced results from two indirect treatm
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a vertically integrated commercial-stage immunotherapy company, today announced that five United States patents
ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced an exclusive U.S. Development and Supply Agreement wit
- Assets Under Management (“AuM”) Increased 12.9% Year-over-Year to $29.0 Billion - - Increased Net Income to $1.9 Million from $1.0 million in the Prior Year - - Increased EBITDA [*] to $3.3 Million from $2.2 Million in the Prior Year - - Total Revenue of $48.7 million similar to $48.9 million in prior year period - NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, today announced results for the quarter ended March 31, 2026. "I am pleased with our strong operational results in the first quarter, despite a sometimes challenging market, as this reflects the continuing growth of our differentiated platform,” stated Craig Gould, Chief Executive Officer of Binah Capital Group.
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively
TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response rate at the 12-month landmark in BCG-Naïve patients
More than 90% of patients surveyed who underwent bladder removal or received BCG report negative impact on most aspects of their lives Among patients treated with BCG, three- quarters describe managing the treatment- related physical symptoms as humiliating Patients and urologists point to the importance of advancing treatments that may better reflect patient preferences and quality-of-life considerations WASHINGTON, May 14, 2026 /PRNewswire/ -- A new global survey of patient and urologist perception and experience—conducted in collaboration with leading bladder cancer professional and patient organizations—reveals the physical, mental, and emotional toll associated with standard-of-care therapies for bladder cancer, including surgery to remove the bladder and Bacillus Calmette-Guérin (BCG) treatment. Released ahead of the American Urological Association (AUA) Annual Meeting, the findings highlight patient experiences that may not always be fully surfaced and discussed during care, pointing to opportunities to strengthen support and continue advancing innovative treatment approaches.
Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a durable 80% CR rate at 12 months in the BCG-unresponsive subpopulation, reinforcing best-in-class potential in NMIBC On track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026 Filed provisional patent application with the USPTO in April 2026 covering NDV-01 pharmaceutical formulations and methods of treatment; if issued, patents claiming priority to the provisional filing would have a term until April 2047 Relmada will feature two NDV-01 presentations at the American Urological Association Annual Meeting (AUA2026), highlighting the 12-month Phase 2 data and the Phase 3 RESCUE program design and rationale Cash balance of $234.0 million as of March 31, 2026 expected to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program Management to host a conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., May 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update.
-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented-
Binah Capital Group, Inc. (NASDAQ: BCG - Get Free Report)'s stock price fell 9% during mid-day trading on Thursday. The company traded as low as $1.82 and last traded at $1.91. 144,432 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 1,703,621 shares. The stock had previously closed
– Grew Total Revenue 11% Year-over-Year to $187.1 Million – – Assets Under Management (“AuM”) Increased 11% Year-over-Year to $29.9 Billion – – Net Income of $2.3 Million – – Increased EBITDA [ * ] to $5.4 Million from $2.0 Million in the Prior Year – NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, today announced results for the quarter and full year ended December 31, 2025. “We completed our first full year as a public company with strong results in the fourth quarter, which reflects the continuing growth of our differentiated platform,” stated Craig Gould, Chief Executive Officer of Binah Capital Group.
Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBC BCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time Tolerability profile remains favorable – no ≥ Grade 3 treatment-related adverse events and no treatment-related discontinuations Data reinforces advancement of NDV-01 into Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026 CORAL GABLES, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced 12-month interim data from its ongoing Phase 2 trial evaluating NDV-01 in patients with high-risk non-muscle invasive bladder cancer (NMIBC).
